Lumipulse® G Pepsinogen I and II

Piecing together the risk factors for stomach cancer

Pepsinogen is a precursor of pepsin, a protease secreted in stomach, and is immunologically categorized into two main classes, pepsinogen I and pepsinogen II. Pepsinogen I exists in fundic gland mucosa, while pepsinogen II exists more broadly, in organs including fundic gland mucosa, cardiac glandpyloric gland, duodenal gland.1 Pepsinogen I value and pepsinogen I / pepsinogen II ratio both correlate with extent of the fundic gland area expansion, and it is useful as a marker of chronic atrophic gastritis progression. Atrophic gastritis progressions is strongly related with stomach cancer,2 and those with severe atrophic change have higher frequency of cancer being found.3-4  


Lumipulse® G Pepsinogen I and II

Lumipulse G Pepsinogen I and II are assay systems, including a set of immunoassay reagents, for the quantitative measurement of pepsinogen I and II in specimens based on CLEIA technology by two-step sandwich immunoassay method on the LUMIPULSE G system (LUMIPULSE G600II and LUMIPULSE G1200). The assays utilise proven CLEIA (ChemiLuminescent Enzyme Immunoassay) technology with results that are available in 30 minutes.

Lumipulse G Pepsinogen I Immunoreaction Cartridges:

  • Art. no. 292983 (3 x 14 Tests) - This product is not available in the USA and in Canada.

Lumipulse G Pepsinogen II Immunoreaction Cartridges:

  • Art. no. 292990 (3 x 14 Tests) - This product is not available in the USA and in Canada.


See the LUMIPULSE G1200 working in this video:


See the LUMIPULSE G600II working in this video:




  1. Sanloff IM, et al. Relationships among serum pepsinogen I, serum pepsinogen II and gastric mucosal histology. Gastroenterology, 83: 204-209, 1982.

  2. Correa P. The gastric precancerous process. Cancer Survey, 2: 438-450, 1983.

  3. Miki K. Gastric Cancer Screening Using Serum Tests (Stomach Dry Dock) -Study of the Systems of the First Screening for Cancer-susceptible Subjects by Serum Pepsinogen Levels and the Secondary Close-examination by Every-Other-Year Panendoscopy. Nippon Shokaki shudankenshin gakkaishi, 84: 141-144, 1989.

  4. Nishizawa M. An outlook of gastric mass screening (1st report). Nippon Shokaki shudankenshin gakkaishi, 84: 141-144, 1989.


You can change the country filter for contents in our website. You will then see local contact information and other information available for that country. Please choose your country in the list below:

Welcome to Fujirebio

It looks as if you are visiting from the United States. The content of this website is not destined for United States visitors.

If you continue your visit you confirm that you understand that not all of the products you will see listed are FDA cleared. FDA cleared products may not be cleared for all indications mentioned on this site. Product claims may differ from country to country based on regulations and approvals.

Please contact your country representative for further details.